TL;DR
- 1.MSTN rs1805086 K153R R-allele carriers produce roughly 20% less effective myostatin. A 71-study meta-analysis found they are twice as likely to be elite strength athletes. The same peptide dose builds measurably more lean mass for them.
- 2.ACTN3 R577X determines your fast-twitch fiber composition. RR carriers generate stronger hypertrophy per GH pulse. XX carriers (18% of Europeans) still respond but with a different muscle composition and a lower absolute ceiling.
- 3.FOXO3 rs2802292 T allele carriers have slower muscle catabolism between doses. They keep peptide gains months after cycling off while others lose lean mass within weeks.
- 4.MK-677 and ipamorelin raise IGF-1, which cross-inhibits myostatin's Smad2/3 signaling pathway. But how much that matters depends entirely on which myostatin variant combination you carry.
- 5.Three of the five variants appear in standard 23andMe raw data. Your myostatin genetics are already available if you have tested.
Two people run the same MK-677 protocol for 12 weeks. Same dose, same diet, same gym. One adds 5 kg of lean mass. The other adds 1.4 kg. The peptide was identical. The difference was not discipline or sleep. It was the myostatin brake sitting in their DNA, calibrated at two very different settings from birth.
Myostatin is the body's primary governor on muscle growth. Follistatin is the natural protein that suppresses it. Your genetics set the starting position of both before you touch any compound. And that baseline changes how much any anabolic peptide can actually do for you. A 2022 meta-analysis of 71 studies published in the journal Genes (PMC9690375) found that carriers of the MSTN K153R variant appear roughly twice as often in elite strength athlete populations as non-carriers. Not 10% more often. Twice.
Carriers of the MSTN K153R variant (rs1805086 R allele) appear twice as often in elite strength athlete populations compared to non-carriers, per a 2022 meta-analysis of 71 studies published in Genes (PMC9690375). The R allele is present in roughly 6 to 8% of European populations.
Here are the five genetic variants that explain most of the unexplained variation in muscle-building peptide response. For each one: what it does, what the data shows, and how it changes which stack to run.
Myostatin is a volume dial on your muscle growth, not an on/off switch. Everyone produces some myostatin. It limits how large muscle fibers can grow after a training or hormonal stimulus. Follistatin is the opposing dial, working in the other direction. Your genetics set both dials at birth. Peptides like MK-677 and ipamorelin can move the myostatin dial indirectly. But if your dial is set to a resistant position by genetics, you need a bigger anabolic signal to move it the same distance as someone whose dial starts closer to off.
Which 5 genetic variants predict myostatin and follistatin response to peptides?
These are not obscure research curiosities. Three of the five appear in standard consumer DNA panels. All five have published human data. And they explain a meaningful share of the variation in lean mass response that peptide communities dismiss as "it's just genetics" without ever naming the specific mechanism.
1. MSTN rs1805086 (K153R): the natural brake release
This is the most studied myostatin variant in human athletic populations. At position 153, the standard allele (K) produces a lysine amino acid. The rare allele (R) substitutes arginine. That substitution partially disrupts the protein's ability to activate the downstream signaling cascade that suppresses muscle fiber growth.
In practice, R allele carriers produce myostatin at normal levels, but each molecule is roughly 20% less effective at suppressing hypertrophy. The 2022 Genes meta-analysis (PMC9690375) combined 71 studies and found the R allele appeared about twice as often in strength-oriented athletes versus controls (OR 2.02, p = 0.05). The R allele is rare in Europeans (6 to 8% carry at least one copy), but the effect is strong enough to show up at population scale across seven decades of sports genetics research.
What this means for peptides: When MK-677 or an ipamorelin stack raises your IGF-1, that elevated IGF-1 activates the PI3K/Akt/mTOR pathway that drives protein synthesis. Akt also phosphorylates and suppresses Smad2 and Smad3, the transcription factors through which myostatin blocks muscle growth. K153R R allele carriers already have partially suppressed Smad signaling from their myostatin. The IGF-1 elevation from a GH secretagogue enters an environment where the brake is already partially released. The same dose produces more. And because the inhibition is genetic, it does not wear off between doses.
2. ACTN3 rs1815739 (R577X): the fast-twitch fiber amplifier
Alpha-actinin-3 is a structural protein found almost exclusively in fast-twitch (type IIx) muscle fibers. The R577X variant produces a premature stop codon. XX carriers produce zero functional alpha-actinin-3. They have normal muscle mass, but structurally different fast-twitch fibers with altered calcium handling, power output characteristics, and mechanical properties under high-force contraction.
A 2024 meta-analysis of 25 studies involving 14,541 participants published in Sports Medicine - Open (El Ouali et al.) found RR carriers are significantly overrepresented in elite power athletes versus endurance athletes (OR 1.27, 95% CI 1.09 to 1.49, p = 0.003). RR carriers also show higher basal testosterone in multiple cohorts. XX carriers, roughly 18% of Europeans, are not disadvantaged for endurance performance, but they have a structural ceiling on explosive fast-twitch hypertrophy that GH secretagogues cannot fully overcome.
"ACTN3 R577X RR genotype was significantly more prevalent in elite power athletes compared to controls across a meta-analysis of 25 studies involving 14,541 participants, with an odds ratio of 1.27 and a 95% confidence interval of 1.09 to 1.49."
Sports Medicine - Open, El Ouali et al., 2024
What this means for peptides: ACTN3 does not interact directly with the myostatin axis. But it determines what the muscle looks like after myostatin is suppressed. An MSTN K153R carrier with ACTN3 RR builds primarily fast-twitch hypertrophy on a GH peptide protocol. An ACTN3 XX carrier on the same protocol builds slower, more mixed-fiber mass. This is why two people can show the same IGF-1 bloodwork response to ipamorelin and still report completely different visual and performance results after 12 weeks.
3. FOXO3 rs2802292: the catabolism gate
FOXO3 is a transcription factor in the forkhead box family. Its primary muscle-relevant function is driving expression of atrogin-1 and MuRF-1, the two main E3 ubiquitin ligases that break down muscle protein during catabolic stress. Lower FOXO3 activity means slower protein degradation during the intervals between doses, during caloric deficits, and after cycling off.
A 2025 systematic review (PMC12654131) confirmed that the myostatin pathway connects directly to FOXO3: myostatin activates Smad2/3, which directly upregulates FOXO3 transcriptional activity, which increases atrogin-1 and MuRF-1 expression. The rs2802292 T allele, the same variant associated with human longevity in FOXO3 research, reduces this transcriptional activity. Carriers of the T allele lose less muscle protein during the off-intervals of any peptide protocol.
What this means for peptides: This variant does not change how much muscle you build during an active protocol. It changes how much you keep when the anabolic signal drops. People who maintain peptide gains for months after cycling off are often T allele carriers running naturally suppressed atrophy signaling. People who lose lean mass within weeks of stopping are often running higher FOXO3 activity with faster protein catabolism once myostatin rebounds. FOXO3 T allele carriers can tolerate longer cycle gaps without losing significant ground.
4. MSTN promoter variants (rs2322757, rs1805065): how much myostatin you actually make
K153R changes the myostatin protein's effectiveness. These promoter variants change how much of the protein your body makes in the first place. They sit in the regulatory region upstream of the MSTN gene that controls transcription rate. Carriers of low-expression promoter haplotypes have lower baseline serum myostatin levels regardless of which protein variant they carry.
This matters because it decouples production from potency. A K153R R allele carrier with a high-output promoter haplotype can still produce enough total myostatin to partially offset the reduced per-molecule potency. Conversely, a standard KK carrier with a low-expression promoter haplotype may have total myostatin output competitive with a K153R carrier. Consumer DNA panels often include rs2322757, which has been associated with differences in serum myostatin levels in sports cohorts.
What this means for peptides: If you run a standard GH secretagogue protocol and consistently underperform expectations without a K153R variant, your promoter genotype is a plausible explanation. Low-expression promoter carriers are already starting from a lower myostatin suppression baseline. They do not need as large a GH-driven IGF-1 elevation to cross the threshold where muscle protein synthesis exceeds myostatin suppression. This is why some KK carriers still build lean mass at a rate that looks like K153R-level response.
5. ACVR2B receptor variants: the receptor-level brake
Myostatin does not act directly on muscle. It binds to activin receptor type IIB (ACVR2B) on the muscle cell surface, which then activates the Smad2/3 signaling cascade. The receptor itself has genetic variants that affect binding affinity. Low-affinity variants hold myostatin less tightly. The signal reaches the Smad pathway less efficiently, even when myostatin levels are completely normal.
This is the same receptor targeted by pharmaceutical myostatin inhibitors. A 2024 meta-analysis of 7 bimagrumab RCTs (PMC11385021) found average lean mass gains of 6 to 8% and preserved fat-free mass, confirming that blocking ACVR2B produces biologically meaningful muscle outcomes at the population level. Natural ACVR2B variants produce a smaller and permanent version of this partial receptor resistance. They appear in consumer DNA data as rs2854464 and related positions.
What this means for peptides: Low-affinity ACVR2B carriers have a structural degree of natural myostatin resistance at the receptor level. Their muscles respond more strongly to any anabolic stimulus because the growth-suppression signal does not land as cleanly as it does in standard-affinity carriers. This is why some users consistently build lean mass across different peptide stacks at a rate that does not correlate with their measured IGF-1 or bloodwork markers. The bottleneck is not at the growth signal. It is at the suppression receptor.
Which peptides affect the myostatin and follistatin axis most directly?
Most anabolic peptides do not target myostatin or follistatin directly. They work upstream through the GH/IGF-1 axis and cross-inhibit myostatin signaling indirectly. Here is how the most common options interact with what your genetics have already set up.
MK-677 (Ibutamoren)
Raises IGF-1 by 40 to 60% in a 12-month RCT in older adults. Elevated IGF-1 activates Akt, which phosphorylates and suppresses Smad2/3. This indirectly cross-inhibits myostatin signaling at the transcription factor level. K153R R allele carriers benefit the most because their Smad signaling was already partially suppressed from the protein level. FOXO3 T allele carriers retain the gains longer when cycling off. For bloodwork timing and dose interpretation, see the two-year MK-677 human trial data review.
Ipamorelin and CJC-1295
The standard GH secretagogue stack. Works through the same IGF-1 route as MK-677 but via pulsatile GH release rather than continuous GH secretagogue stimulation. ACTN3 RR carriers build primarily fast-twitch hypertrophy with better power output results. ACTN3 XX carriers typically see more body recomposition (fat loss plus moderate lean mass gain) than outright hypertrophy. See the genotype-based ipamorelin and CJC-1295 dosing guide for protocol specifics.
BPC-157
No direct myostatin or follistatin interaction appears in the published literature. BPC-157's relevance to the myostatin axis is indirect: it upregulates GH receptor expression in fibroblasts, which can amplify the tissue-level response to whatever IGF-1 is circulating from a concurrent GH secretagogue stack. It is most useful in this context as a recovery complement rather than a substitute for growth-axis peptides. For where it fits in a muscle-building protocol, see how the evidence ranks muscle recovery peptides.
How to find your myostatin and ACTN3 genotypes in 23andMe data
Three of the five variants above appear on standard consumer DNA arrays. If you have tested with 23andMe, AncestryDNA, or MyHeritage, this information is sitting in a downloadable raw data file you already own.
| Variant | Gene | rsID | In 23andMe | What to look for |
|---|---|---|---|---|
| K153R | MSTN | rs1805086 | Yes | KR or RR (may appear as AA or AG depending on strand orientation) |
| R577X | ACTN3 | rs1815739 | Yes | RR, RX, or XX (may appear as CC, CT, or TT) |
| Longevity T allele | FOXO3 | rs2802292 | Yes | T allele at this position reduces catabolism activity |
| Promoter low-expression | MSTN | rs2322757 | Partial | Low-expression alleles reduce total myostatin production |
| Receptor sensitivity | ACVR2B | rs2854464 | Partial | Low-affinity alleles reduce myostatin binding at muscle receptors |
The raw data file uses rsIDs directly. Search for each identifier. The allele letter in your file may differ from the published risk notation depending on which DNA strand the array genotyped. The guide to reading 23andMe data for peptide response explains how to convert between strand orientations and which providers cover each variant.
Your PeptidesDNA report pulls all five myostatin-axis variants and scores your genotype combination against the MK-677 genetic match profile alongside the full peptide panel. For how the growth hormone receptor genetics interact with the myostatin axis above this, see why two people on the same ipamorelin protocol get completely different IGF-1 results.
Verdict: The gap between 1.4 kg and 5 kg of lean mass on the same 12-week GH peptide protocol is not discipline or diet. It is usually two or three genetic variables working together: a high-output MSTN promoter, a standard K153R genotype, and an ACTN3 XX phenotype that limits fast-twitch hypertrophy ceiling. MSTN rs1805086 and ACTN3 rs1815739 are both in your 23andMe raw data right now. FOXO3 rs2802292 is there too. Check them before assuming your next protocol needs a higher dose. It may need a different approach entirely. Upload your genetic data or order a DNA kit to get your full myostatin-axis profile alongside the complete peptide match report.
Your DNA shapes how you respond to every peptide in this report.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
What is myostatin and why does it affect peptide results?
Myostatin is a protein produced by muscle tissue that limits how large muscle fibers can grow. It binds to the ACVR2B receptor on muscle cells and activates a signaling cascade through Smad2 and Smad3 that suppresses protein synthesis. Anabolic peptides like MK-677 and ipamorelin raise IGF-1, which in turn activates the Akt pathway that cross-inhibits Smad2/3. This is how GH secretagogues partially counteract myostatin signaling. But if your myostatin levels are genetically high or your receptor affinity is above average, you need a larger IGF-1 elevation to produce the same muscle-building effect as someone with a genetically lower myostatin baseline.
Do I have the myostatin mutation? How do I check?
The primary myostatin variant studied in athletic populations is MSTN rs1805086 (K153R). The R allele is the variant that partially reduces myostatin's effectiveness. You can look it up in your 23andMe, AncestryDNA, or MyHeritage raw data file by searching for rs1805086. Your genotype will appear as a two-letter code. The raw data may label the alleles differently from the K and R naming convention depending on strand orientation. About 6 to 8% of Europeans carry at least one R allele. Two copies (RR) is uncommon but documented in athletic populations. One copy (KR) still confers a measurable advantage per the 71-study meta-analysis.
What is ACTN3 R577X and does it affect how peptides build muscle?
ACTN3 rs1815739 is one of the most studied genetic variants in sports science. The R allele produces functional alpha-actinin-3, a structural protein in fast-twitch muscle fibers. The X allele produces a non-functional version. XX carriers have no alpha-actinin-3. This does not prevent muscle growth, but it changes the composition: XX carriers build more mixed-fiber mass with less pure type IIx fast-twitch hypertrophy. On a GH secretagogue like MK-677, RR carriers tend to see more raw hypertrophy while XX carriers see more body recomposition. Knowing your ACTN3 genotype helps you set realistic expectations for what any peptide will produce in your specific muscle fiber makeup.
Why do some people keep muscle after stopping peptides while others lose it quickly?
The most likely genetic explanation is FOXO3. The FOXO3 transcription factor drives expression of atrogin-1 and MuRF-1, the two primary muscle-degrading enzymes. The myostatin pathway activates FOXO3, so when you cycle off and myostatin rebounds, FOXO3 activity rises and protein catabolism increases. Carriers of the rs2802292 T allele run lower baseline FOXO3 activity. Their atrophy signaling is blunted even as myostatin rebounds. They keep more lean mass during cycle gaps and off-cycles. Carriers without the T allele experience faster protein degradation when the anabolic signal drops and need shorter off-periods or lower-maintenance dosing to preserve gains.
Can peptides compensate for high-myostatin genetics?
Partially, but not completely. GH secretagogues raise IGF-1, which cross-inhibits the Smad signaling pathway through which myostatin suppresses muscle growth. A large enough IGF-1 elevation can meaningfully reduce the net myostatin effect even in high-expression promoter carriers. But the pharmaceutical evidence puts this in perspective: bimagrumab, a drug that directly blocks the ACVR2B receptor, produces 6 to 8% lean mass gains in RCTs. Peptides that work indirectly through IGF-1 will produce a smaller fraction of that effect, scaled by how much your IGF-1 actually rises and how efficiently your cells use it. High-myostatin-genetics users benefit from tracking bloodwork and optimizing IGF-1 response before concluding a protocol is not working.
Is follistatin-344 a peptide I can legally buy and use?
FST-344 (follistatin-344) is a research compound, not an approved drug or a peptide with an established compounding pathway. It is prohibited under WADA rules (Hormone and Metabolic Modulators, S4.3) for competitive athletes. Vendors sell it under research-use-only disclaimers, which carry the same legal exposure as other unapproved injectable research compounds. No human clinical trial has been completed on injectable FST-344 in healthy individuals. The FDA has not approved it and it is not on the 503A compounding nominee list. AAV-based follistatin gene therapy is separately prohibited as gene doping. The myostatin-axis peptides with current human safety and compounding data are the GH secretagogues (ipamorelin, CJC-1295, MK-677) that work indirectly through the same pathway.
How do MSTN genetics affect results on MK-677 specifically?
MK-677 raises IGF-1 via sustained ghrelin receptor activation. Elevated IGF-1 activates the Akt signaling cascade, which phosphorylates and inhibits the Smad2/3 transcription factors that myostatin normally uses to suppress muscle growth. MSTN K153R R allele carriers already have weaker per-molecule myostatin signaling. Adding the Smad2/3 cross-inhibition from elevated IGF-1 compounds the effect: the brake is partially released from two directions simultaneously. The 12-month RCT data on MK-677 in older adults showed average fat-free mass gains of roughly 1 to 2 kg. K153R carriers, based on the population-level athletic data, would be expected to sit toward the upper end of that response distribution. Bloodwork at weeks 4 and 12 is the practical screen for where you land.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.